Skip to main content

IFRX

Stock
Health Care
Biotechnology

Performance overview

IFRX Price
Price Chart

Forward-looking statistics

Beta
1.01
Risk
82.97%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Company info

SectorHealth Care
IndustryBiotechnology
Employees43
Market cap$94.8M

Fundamentals

Enterprise value-$13.7M
Revenue$152.6K
Revenue per employee
Profit margin-1900.76%
Debt to equity1.00

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.87
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$532K
Avg trading volume (10 day)$140K
Put-call ratio

Macro factor sensitivity

Growth+3.5
Credit+0.4
Liquidity-1.7
Inflation+4.1
Commodities+2.4
Interest Rates-0.4

Valuation

Dividend yield0.00%
PEG Ratio-0.76
Price to sales418.96
P/E Ratio-0.76
Enterprise Value to Revenue-89.69
Price to book0.77

Upcoming events

Next earnings dayMay 7, 2025
Next dividend day
Ex. dividend day

News

InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease

InflaRx N.V. IFRX on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) recommended that the trial be stopped due to futility.

Benzinga (May 28, 2025)
InflaRx (IFRX) Loses -15.29% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

InflaRx (IFRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research (March 26, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free